You are here

Article Text

Article menu
Download PDFPDF
Successful treatment of recalcitrant condyloma with topical cidofovir
  1. U R Hengge,
  2. G Tietze
  1. Department of Dermatology and Venerology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany
  2. Hospital Pharmacy, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany
  1. U R Henggedermatology{at}uni-essen.de

https://doi.org/10.1136/sti.76.2.143

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Editor,—Despite the high prevalence of condylomata acuminata, their treatment remains unsatisfactory for both patients and physicians. Epidemiological studies estimated the prevalence of genital warts between 1–31% with a peak occurring in young adults.1 As a consequence, the economic burden of human papillomavirus (HPV) infection in the United States is estimated to exceed $8.5 billion per year.2 Current treatments rely on the ablation of warts (cryotherapy, laser vaporisation, electrodissection, or trichloroacetic acid) or the interruption of cell division (podophylox, intralesional or systemic interferon, and 5-fluorouracil). Recently, imiquimod has been successfully used as a topical immune response modifier for the treatment of external anogenital warts.3 However, there remains a substantial number of patients who fail to respond …

    View Full Text